Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online:138
  • Home
  • Print this page
  • Email this page


 
 Table of Contents  
ORIGINAL ARTICLE
Year : 2014  |  Volume : 13  |  Issue : 1  |  Page : 24-29

Salivary gland tumors, a twenty-year retrospective study


1 Department of Pathology, Central Hospital, Benin City, Nigeria
2 Department of Histopathology, University of Benin Teaching Hospital, Benin City, Nigeria

Date of Web Publication25-Aug-2014

Correspondence Address:
Dr. Uchendu Obiora Jude
Department of Pathology and Forensic Medicine, Central Hospital, Benin City, Edo State
Nigeria
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2384-5589.139439

Rights and Permissions
  Abstract 

This is a retrospective study of salivary gland tumor (SGT) specimens seen at the University of Benin Teaching Hospital (UBTH) over a 20-year period. It is aimed at determining the epidemiological pattern of these tumors. The materials for this study that consisted of available slides and paraffin-embedded blocks of all SGT specimens received during the study period were evaluated. Data on age, sex, anatomical sites and histologic diagnosis were obtained from the departmental surgical records. Data analysis was done using SPSS version 16.0. SGTs are very rare, accounting for 0.32% of specimens received in the UBTH. The female to male ratio was 1:1.3, and the ratio of benign to malignant tumors was 1.8:1. The mean ages for benign and malignant tumors were 37.0 and 43.5 years, respectively. The peak age for benign SGTs was in the 3 rd decade, while malignant tumors showed a peak in the 6 th decade. The parotid gland was most commonly affected (57%). Overall, pleomorphic adenoma was the most common SGT seen, accounting for 53.2% of all the cases. Adenoid cystic carcinoma was the most frequently encountered malignant SGT (10.1%). The epidemiological pattern of SGT in the study populace is similar to those of other African-based studies but differ slightly from those of the Caucasians.

Keywords: Retrospective, salivary, tumor


How to cite this article:
Jude UO, Olu-Eddo AN. Salivary gland tumors, a twenty-year retrospective study. Afr J Med Health Sci 2014;13:24-9

How to cite this URL:
Jude UO, Olu-Eddo AN. Salivary gland tumors, a twenty-year retrospective study. Afr J Med Health Sci [serial online] 2014 [cited 2019 Apr 26];13:24-9. Available from: http://www.ajmhs.org/text.asp?2014/13/1/24/139439


  Introduction Top


The salivary glands are responsible for the production, modification and secretion of saliva, which aid mastication, deglutition, digestion and protection of teeth and soft tissues. [1] These are exocrine glands, organized into major bilaterally paired glands (parotid, submandibular and sublingual glands) and minor glands, located throughout the oral and the oropharyngeal mucosa. Ectopic salivary glands have also been reported commonly in the periparotid and intraparotid lymph nodes, soft tissue and other organs in the head, neck and chest region, rectum, vulva, stomach, pterygopalatine fossa and cellebellopontine angle. These glands recapitulate normal salivary glands. [1],[2]

Salivary glands often give rise to different pathologic conditions, ranging from cystic, inflammatory, tumor-like and neoplastic lesions. [1] Salivary gland tumors (SGT) are particularly important to the pathologist and the head and neck surgeons because of their associated morbidity and mortality, and more specially because important head and neck structures like the facial nerve transverse these glands. [2]

Despite the relatively simple morphology of the salivary gland, over 35 different neoplasms have been associated with them. [1] Considering the diverse anatomical sites and histological subtypes, it is easy to understand why otolaryngologists, head and neck surgeons, oncologists and pathologists accumulate only restricted exposure to specific types of SGTs. [3],[4] Heterogeneity within the individual histological subtype also posses further diagnostic challenge to the pathologist. [4]

Studies have shown significant geographical variation in incidence of these tumors. It is however estimated that SGT accounts for 0.5-2% of all tumors globally [5] and between 3-6% and 2.8-10% of head and neck tumors in western countries and Africa, respectively. [6]

The earliest study of SGTs as a distinct entity in Nigeria was performed by Edington and Shelhan in Ibadan. [7] Since then, a few other studies have been performed across the country, mostly in Ibadan, Lagos, Enugu, Maiduguri, Ife and Jos. [8]

This study presents the first comprehensive study of the histological pattern of SGTs in the University of Benin Teaching Hospital (UBTH), aimed at understanding the epidemiological pattern of these tumors and to compare our findings with reports done elsewhere.


  Materials and Methods Top


This is a 20-year retrospective study of biopsied salivary gland specimens received at the Department of Histopathology, UBTH, Benin City, Edo State, Nigeria, between January 1990 and December 2009. Cases histologically diagnosed as SGTs formed the focus of this study. These biopsies were received from the UBTH and other hospitals within Edo state and its neighboring states.

Information relevant for this study was retrieved from the surgical pathology register. Additional information where necessary was retrieved from duplicate copies of histological reports and the case notes of the patients. Corresponding slides were also retrieved and, where necessary, new sections were made from the corresponding paraffin-embedded tissue blocks. These sections were later stained with hematoxylin and eosin stains. Special stains were applied where necessary.

These SGTs were classified in accordance with the 2005 World Health Organization (WHO) Histological Classification of Salivary Gland Tumours, [9] and their frequency distribution was analyzed using SPSS version 16.0 (Microsoft Corporation, Chicago, 2007) and presented in tables and figures.

Exclusion Criteria

Cases with recurrence, unknown origin and uncertain histological diagnosis were excluded from this study. Specimens in which the corresponding slides or tissue blocks could not be retrieved were also excluded from the study.

Ethical Approval

This study was approved by the ethical clearance committee of the UBTH, Benin City (ADM/E 22A/VOL VII/296), before the work was commenced.


  Results Top


A total of 38,000 surgical specimens were received in the Department of Pathology, UBTH, during the study period. Of these, 8500 specimens were neoplastic. SGTs accounted for 123 cases, constituting 0.32% of all surgical specimens and 1.43% of all neoplasms received. Of the 123 cases of SGTs received, 109 cases met the inclusion criteria and were used for this study.

The study shows a stable incidence of SGTs within the study period, with double peaks in 2005 and 2009. The average incidence of SGTs is 5.5 cases annually. Details of the yearly distribution of SGTs are shown in [Figure 1] and [Figure 2].
Figure 1: Yearly distribution of all salivary gland tumors

Click here to view
Figure 2: Yearly trend of the dominant salivary gland tumors

Click here to view


The age range of patients was 2-75 years, with a mean age of 39.34 ± 17.19 years. The mean ages for benign and malignant SGTs were 37.03 ± 15.44 and 43.50 ± 19.46 years, respectively. The peak incidence for the benign and the malignant tumors were in the 3 rd and 6 th decades, respectively. The age distribution of SGTs is shown in [Table 1] and [Figure 3].The age range and mean age of various SGTs is also shown in [Table 2].
Figure 3: Comparison of cases of salivary gland tumors across various age groups

Click here to view
Table 1: Age group distribution of salivary gland tumors

Click here to view
Table 2: Age range, mean age and standard deviation of SGTS

Click here to view


Forty-four percent of the cases occurred in males, giving an M:F ratio of 1:1.3 for all SGTs. An M:F ratio of 1:1.26 was observed for both the benign and the malignant SGTs.

The anatomical distributions of the tumors include parotid gland (57%), submandibular gland (16%) and minor salivary glands (27%). The palate, buccal mucosa, tongue, lip, retromolar mucosa and neck were the anatomical sites of the minor SGTs in this study, with the palate accounting for 79% of the cases. The benign-malignancy ratio for the parotid, minor salivary gland and the submandibular tumors were 1.3:1, 1.9:1 and 4.6:1, respectively.

Sixty-four percent of these tumors were benign, with pleomorphic adeoma accounting for 83% of them. Other benign tumors seen in this study were basal cell adenoma, adenolymphoma (Warthin's tumor), capillary hemangioma, myoepithelioma and fibrolipoma.

The most common malignant tumors in this study were adenoid cystic carcinoma, mucoepidermoid carcinoma and acinic cell carcinoma, accounting for 28.2%, 23.1% and 18% of all malignant tumors seen. Few cases of squamous cell, basal cell, salivary duct and small cell carcinomas, sialoblastoma, hemangiopericytoma, myxoid liposarcoma and polymorphous low-grade adenocarcinoma were also seen.


  Discussion Top


In this study, SGTs accounted for 1.43% of all neoplasm seen at the histopathology unit of the UBTH. This is similar to the findings by Ochicha et al.[10] in Kano, northern Nigeria, but lower than the 2% reported in the western population. [3],[9] This difference may be explained by the poor health-seeking behaviors of our populace. Also, there may be slight variations in the geographical distributions of various neoplasms. Our findings are also remarkably lower than the report from the Canadian Eskimos where SGTs accounted for a quarter of all malignant tumors seen in their population. [11]

A stable incidence of SGTs was noted with peaks in 2005 and 2009. We have no explanation for these peaks. This may call for further investigations.

The age of patients seen in this study ranged from 2 to 75 years. This parallels the reports from Ochicha et al. in Kano, Nigeria (13-65 years), [10] Bahra et al. in Kenya (8-80 year) [12] and Thomas et al. in Malawi (1-75 years). [13] Our findings are however at variance with reports in the western literature, where SGTs occurred over a wider age group with a peak age reported in the 7 th and 8 th decades. [4],[9] It can therefore be implied that there are relatively more elderly patients with SGTs in the western population. The fewer number of elderly patients seen in African studies may be ascribed to its lower life expectancy.

The peak for benign and malignant SGTs was observed in the 3 rd and 6 th decades, respectively. Similarly, Otoh et al. in Maiduguri (Nigeria), [14] Silas et al. in Jos (Nigeria) [15] and Chatterge et al. in Asia [16] reported a peak incidence in the 3 rd decade for benign SGTs. In Ibadan (Nigeria) [17] and in South Africa, [18] a peak incidence for benign tumors was reported in the 4 th decade. On the contrary, the peak incidence in the 5 th decade was reported among Caucasians for benign SGTs. [9] Abiose et al. in Ibadan (Nigeria), [17] Van heerden in South Africa, [18] Vulhulu in Uganda [19] and Chatterge in Asia [16] reported a peak for malignant tumors, a decade lower than our observation. On the contrary, studies has shown that the peak incidence for malignant tumors among Caucasians occurred in the 7 th and 8 th decades. [9] The mean age of presentation for benign and malignant tumors in our study were 37.03 and 49.10, respectively, which is comparable to other African reports with a mean age range of 25-45 and 45-55 years, respectively, for the benign and malignant tumors. [7],[17],[18] Comparatively, reports from Europe and the US show that the mean age for benign and malignant SGTs are either a decade or two later than the observations from African studies. [9] This difference may be attributed to our low life expectancy and probable genetic or environmental factors that are unique to the African population.

There were more females than males with SGTs in this study population, which is similar to the previous studies performed in Ibadan (Nigeria), [7] Enugu (Nigeria), [20] Uganda, [19] Zimbabwe, [21] Kenya [22] and the UK. [23] Equal gender distribution was reported in India, [16] Parkistan, [24] Brazil [25] and in another study in Ibadan (Nigeria), [17] while in Tanzania a male dominance was reported. [26] There was no significant association between the gender of our patients and the histological type of SGT.

Apart from the sublingual gland that was not involved, all other major salivary glands were affected. The percentage distributions were 57%, 16% and 27% and for the parotid, submandibular and minor salivary glands, respectively, giving an approximate ratio of 3.5:1:1.5. Our finding is slightly similar to the 1:1:1 ratio reported in Uganda [19] and the 2:1:1 ratio reported in Kano (Nigeria). [10] On the contrary, salivary neoplasm follows a distribution ratio of 100:10:10 in Europe and the US. [4] The low prevalence of sublingual tumors, as seen in this study, is similar to its general global low incidence. [4],[7],[19]

The incidence of parotid tumor in our report (57%) is comparable to the 60% reported by Ezeanolue et al. in Enugu (Nigeria) and Moatemri et al. in Tunisia. [20],[27] Our review is however intermediate between the 32% and 49% reported in other African series and the 71% and 80% reported in Asia, South America, Europe and the US. [4],[10],[14],[16],[19],[26],[28],[29]

The palate was the most common site affected among the minor salivary glands, accounting for 21% of all SGTs and 79% of minor SGTs. This is comparable to the reports by Ochich et al. in Kano (Nigeria), Thomas et al. in Malawi and Massanja et al. in Tanzania, where palatine tumors accounted for 15%, 18.9% and 24%, respectively, of all SGTs. [10],[13],[26] This is however at variance with the findings in Europe where palatine tumors accounted for 3.8-7.5% of SGTs. [30]

Our present data show a high prevalence of benign tumors, giving an approximate benign-malignancy ratio of 2:1, which is similar to the findings in China and the UK. [23],[31] This is however intermediate between the 1:1 ratio reported in Ibadan (Nigeria), Kano (Nigeria), Kenya, Tanzania and Uganda and 3-4:1 ratio reported in Zimbabwe and Pakistan. [7],[10],[19],[21],[22],[26] This may be attributed to the differences in methodologies and inclusion criteria used in the different studies.

Pleomorphic adenoma was the most common SGT in our study, accounting for 87% of all benign cases and 53.5% of all cases. This finding is consistent with its general global high incidence. [7] A mean age of 37.1 years was reported in our study for pleomorphic adenoma, which is similar to the mean age of 31 years reported by Odukoye et al. in Lagos (Nigeria), but about a decade lower than the mean age reported among the European population. [4],[32] This difference may also be explained by the low life expectancy of the study population, which was 51.9 years as in 2011. [33]

It has been generally observed that Warthin's tumor is very rare in African series. [7],[10],[12],[18],[21],[22],[26] This is evident in our study, as only a single case was found in our 20-year audit of SGTs. However, in India, China, Europe and America, Warthin's was reported as the second most common benign SGT. [23],[31],[34] It has earlier been adduced that there is a strong association between cigarette smoking and the incidence of Warthin's tumor; the relatively lower rate of smoking as compared with the Asian and Western populations may partly explain this difference in incidence. [35]

Considering only the malignant tumors, adenoid cystic carcinoma was the most common condition in this sample (28.8%), followed by mucoepidermoid carcinoma (23%). As in our study, some reports have suggested that adenoid cystic carcinoma is the most common malignant SGT. [19],[21],[22],[26],[31] Other researchers have however reported that mucoepidermoid carcinoma is the most common malignant SGT. [10],[34],[36] However, there is no doubt in the literature that either mucoepidermoid or adenoid cystic carcinoma has remained the most common malignant SGT globally.

A changing pattern in the incidence of these two tumors was observed in our study. Mucoepidermoid carcinoma was the predominant malignant tumor in the first decade of our study, with the second malignant SGT accounted for by adenoid cystic carcinoma. A relatively sharp rise in the incidence of adenoid cystic carcinoma was observed in the second decade of this study, with adenoid cystic carcinoma becoming the most common malignant SGT. This finding of a changing pattern in the occurrence of these malignant SGTs in our environment calls for further research.

Acinic cell carcinoma was the 3 rd most common malignant SGT in this study, accounting for 6.4% of all SGTs and 18% of malignant SGTs, and having a female to male ratio of 6:1. Our finding was comparable to the report from Eveson et al., where acinic cell carcinoma showed a female predominance and accounted for 17% of malignant SGTs. [4]

The rarity of polymorphous low-grade adenocarcinoma, carcinosarcoma, small cell carcinoma, salivary duct carcinoma, sialoblastoma, myxoid liposarcoma, capillary hemangioma and fibrolipoma in our study is comparable to their general global low incidence. [9]


  Conclusion Top


We found a mean annual incidence of SGTs of 5.5 cases. The peak incidences of benign and malignant tumors were in the 3 rd and 6 th decades, respectively. Pleomorphic adenoma and adenoid cystic carcinoma were the most common benign and malignant SGTs in our study populace.

 
  References Top

1.Gnepp RD, Simpson RH, Eveson J. Salivary and Lacrimal gland. In: Gnepp RD, editor. Diagnostic surgical pathology of the Head and Neck. 2 nd ed. Philadelphia: Saunders; 2012. p.413-38.   Back to cited text no. 1
    
2.Kontis TC, John ME. Anatomy and physiology of the salivary glands. In: Bailey BJ, editor. Head and neck surgery-otolaryngology. 2 nd ed. Philadelphia: Lippincott-Raven Publishers; 1998. p. 531-9.  Back to cited text no. 2
    
3.Lingen MW. Head and Neck. In: Kumar V, Abbas AK, Fausto N, Aster JC, editors. Robbins and cotran pathologic basis of disease. 8 th ed. Philadelphia: Saunders; 2010. p. 757-61.  Back to cited text no. 3
    
4.Eveson JW, Cawson RA. Salivary gland tumours: A review of 2410 cases with particular reference to histological type, site, age and sex distribution. J Pathol 1985;146:51-8.  Back to cited text no. 4
[PUBMED]    
5.Auclair PL, Ellis GL, Gnepp DR,Wenig BM, Janney CG. Salivary gland neoplasm: General consideration. In: Ellis GL, Auclair PL, Gnepp DR, editors. Surgical pathology of the salivary glands: Major problems in Pathology. Philadelphia: W B Saunders; 2000. p. 135-64.  Back to cited text no. 5
    
6.Yaor MA. The pattern of presentation of salivary gland tumours in Africa: A review of published reports. Ear Nose Throat J 2010;89:17.  Back to cited text no. 6
    
7.Edington GM, Sheiham A. Salivary gland tumours and tumours of the oral cavity in western Nigeria. Br J Cancer 1996;10:425-33.  Back to cited text no. 7
    
8.Kolude B. The Salivary gland tumurs: The revelations, reproach and remedies. College of Medicine Lecture Series 2012.  Back to cited text no. 8
    
9.Eveson JW, Auclair P, Gnepp DR, El-Naggar AK. Tumours of the salivary glands: Introduction. In: Barnes L, Eveson JW, Reichat P, Sidranksky D, editors. Pathology and genetics of head and neck tumours. Lyon; 2005. p. 212.  Back to cited text no. 9
    
10.Hildes JA, Schaefer O. The changing picture of neoplastic disease in the western and cenral Canadian Actic (1950-1980). Can Med Assoc J 1984;130:25-32.  Back to cited text no. 10
[PUBMED]    
11.Ochicha O, Salami S, Mohammed A, Atanda A. A histopathologic study of salivary gland tumours in Kano, northern Nigeria. Indian J Pathol Microbiol 2009;52:473-6.   Back to cited text no. 11
[PUBMED]  Medknow Journal  
12.Bahra J, Butt F, Dimba E, Macigo F. Patterns of salivary tumours at a university teaching hospital in Kenya. Open J Stomatol 2012;2:280-5.  Back to cited text no. 12
    
13.Thomas KM, Hutt MR, Borgstein J. Salivary gland tumours in malawi. Cancer 1980;46:2328-34.  Back to cited text no. 13
    
14.Otoh EC, Johnson NW, Olasoji H, Danfillo IS, Adeleke OA. Salivary gland neoplasms in Maiduguri, north-eastern Nigeria. Oral Dis 2005;11:386-91.  Back to cited text no. 14
    
15.Silas OA, Echejoh GO, Menesseh AN, Mandong BM, Otoh EC. Desccriptive pattern of salivary gland tumours in jos university teaching hospital: A 10-year retrospective stude. Ann Afr Med 2009;8:199-202.  Back to cited text no. 15
[PUBMED]  Medknow Journal  
16.Chattergee MT, Panda PK. A pathological study of benign and malignant tumours of salivary glands. MJAFI 2000;56:282-6.  Back to cited text no. 16
    
17.Abiose BO, Oyejide O, Ogunniyi J. Salivary gland tumours in Ibadan, Nigeria: A study of 295 cases. Afr J Med Sci 1990;19:195-9.  Back to cited text no. 17
    
18.Van Heerden WF, Raubenheimer EJ. Intraoral salivary gland neoplasm: A retrospectivestudy of 70 cases in an African population. Oral Surg Oral Med Oral Pathol 1991;71:579-82.   Back to cited text no. 18
    
19.Vuhahula EA. Salivary gland tumors in Uganda: Clinical pathological study. Afr Health Sci 2004;4:15-23.  Back to cited text no. 19
[PUBMED]    
20.Kasangaki A, Kamulegeye A. Neoplasms of the salivary glands: A descriptive retrospective study of 142 cases-Mulago Hospital Uganda. J Contemp Dent Pract 2004;5:16-27.  Back to cited text no. 20
    
21.Chidzonga MM, Lopez Perez VM, Portilla Alvarez AL. Salivary gland tumours in Zimbabwe: Report of 282 cases. Int J Oral Maxillofac Surg 1995;24:293-7.  Back to cited text no. 21
    
22.Onyango JF, Awange DO, Muthamia JM, Muga BI. Salivary gland tumours in Kenya. East Afr Med J 1992;69:525-30.  Back to cited text no. 22
    
23.Jones AV, Craig GT, Speight PM, Franklin CD. The range and demographics of salivary gland tumours diagnosed in a UK population. Oral Oncol 2008;44:407-17.  Back to cited text no. 23
    
24.Shaikh AM, Kehar SI, Tariq N. Spectrum of salivary gland lesions and frequency of adenoid cystic carcinoma in salivary glands and extra salivary sites. Pak J Otolaryngol 2010;26:37-9.  Back to cited text no. 24
    
25.Ito FA, Ito K, Vargas PA, de Almeida OP, Lopes MA. Salivary gland tumours in a Brazilian population. A retrospective study of 496 cases. Int J Oral Maxillofac Surg 2005;34:533-6.  Back to cited text no. 25
    
26.Massanja MI, Kalvanyama BM, Simon EN. Salivary gland tumurs in Tanzania. East Afr Med J 2003;80:429-34.  Back to cited text no. 26
    
27.Moatemri R, Belajouza H, Farroukh U, Ommezzine M, Slama A, Ayachi S, et al. Epidemiological profile of salivary-glands tumors in a Tunisian teaching hospital. Rev Stomatol Chir Maxillofac 2008;109:148-52.  Back to cited text no. 27
    
28.Vargas PA, Gerhard R, Araújo Filho VJ, de Castro IV. Salivary gland tumors in a Brazilian population: A retrospective study of 124 cases. Rev Hosp Clin 2002; 57:271-6.  Back to cited text no. 28
    
29.Arotiba GT. Salivary gland neoplasms in Lagos. East Afr Med J 1996;72:560-3.   Back to cited text no. 29
    
30.Sharkey FE. Systematic evaluation of World Health Organization Classification of salivary gland tumors. A clinicopathologic study of 366 cases. Am J Clin Pathol 1977;67:272-8.  Back to cited text no. 30
[PUBMED]    
31.Tian Z, Li L, Wang L, Hu Y, Li J. Salivary gland neoplasms in oral and maxillofacial regions: A 23-year retrospective study of 6982 cases in an eastern Chinese population. Int J Oral Maxillofac Surg 2010;39:235-42.  Back to cited text no. 31
    
32.Odukoya O. Pleomorphic adenoma of the salivary glands in Lagos, Nigeria: Clinicopathological analysis of 45 cases. Cent Afr J Med 1990;36:251-6.  Back to cited text no. 32
[PUBMED]    
33.African Development Bank Group Report on Federal Republic of Nigeria, Country Strategy Paper 2013-2017. Published on January 2013.  Back to cited text no. 33
    
34.Rajesh SL, Arum KK, Gayatri DP, Sharmila L, Kaushik D. Pattern of Salivary gland tumours in Manipuur, India: A 10 year study. South Asian J Cancer 2013; 2:250-3.  Back to cited text no. 34
    
35.Pinkston JA, Cole P. Cigarette smoking and Warthin's tumour. Am J Epidemiol 1996;144:183-7.  Back to cited text no. 35
    
36.Pinkston JA, Cole P. Incidence rates of salivary gland tumours: Results from a population-based study. Otolaryngol Head Neck Surg 1999;120:834-40.  Back to cited text no. 36
    


    Figures

  [Figure 1], [Figure 2], [Figure 3]
 
 
    Tables

  [Table 1], [Table 2]


This article has been cited by
1 Descriptive epidemiology of salivary gland neoplasms in Nigeria: An AOPRC multicenter tertiary hospital study
Olufemi Gbenga Omitola,Olujide Oladele Soyele,Azeez Butali,Abdulwarith Olaitan Akinshipo,Dickson Okoh,Opeyemi Sigbeku,Olajumoke Ajibola Effiom,Kehinde Emmanuel Adebiyi,Adeola Mofoluwake Ladeji,Akinyele Olumuyiwa Adisa,Ahmed Oluwatoyin Lawal,Osareniye Osayande,Ramat Oyebunmi Braimah,Henry Ademola Adeola
Oral Diseases. 2018;
[Pubmed] | [DOI]
2 Descriptive analysis of neoplasias diagnosed as pleomorphic adenoma (PA) that presented at the University of Nigeria Teaching Hospital Ituku-Ozalla Enugu
Onuorah Akpeh James,Chukwuemeka Okechi Uchenna,Amaechi Agu Kenneth,Chukwuemeka Ezeanolue Basil
International Journal of Medicine and Medical Sciences. 2018; 10(1): 14
[Pubmed] | [DOI]
3 Pattern of Salivary Gland Tumour in Sokoto, North-Western Nigeria
Daniel Aliyu,Kufre Robert Iseh,Saddiku Mallami Sahabi,Stanley Baba Amutta,Mohammed Abdullahi,Mfon Ime Inoh
International Journal of Clinical Medicine. 2016; 07(05): 347
[Pubmed] | [DOI]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
   Abstract
  Introduction
   Materials and Me...
  Results
  Discussion
  Conclusion
   References
   Article Figures
   Article Tables
 Article Access Statistics
    Viewed2857    
    Printed112    
    Emailed0    
    PDF Downloaded213    
    Comments [Add]    
    Cited by others 3    

Recommend this journal

[TAG2] [TAG3] [TAG4]